Next Article in Journal
Theranostic Probes for Targeting Tumor Microenvironment: An Overview
Previous Article in Journal
An AAAG-Rich Oligodeoxynucleotide Rescues Mice from Bacterial Septic Peritonitis by Interfering Interferon Regulatory Factor 5
Previous Article in Special Issue
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
Letter published on 19 June 2017, see Int. J. Mol. Sci. 2017, 18(6), 1308.
Article

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

1
Lung Cancer Unit, IRCCS AOU San Martino—IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, 16132 Genova, Italy
2
Clinical Epidemiology Unit, IRCCS AOU San Martino—IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, 16132 Genova, Italy
3
Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, IRCCS AOU San Martino—IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, 16132 Genova, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2017, 18(5), 1035; https://doi.org/10.3390/ijms18051035
Received: 7 April 2017 / Revised: 4 May 2017 / Accepted: 5 May 2017 / Published: 11 May 2017
Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the prognostic role of cfDNA and CTCs, in separate and joint analyses, in NSCLC patients receiving first line chemotherapy. Seventy-three patients with advanced NSCLC were enrolled in this study. CfDNA and CTC were analyzed at baseline and after two cycles of chemotherapy. Plasma cfDNA quantification was performed by quantitative PCR (qPCR) whereas CTCs were isolated by the ScreenCell Cyto (ScreenCell, Paris, France) device and enumerated according to malignant features. Patients with baseline cfDNA higher than the median value (96.3 hTERT copy number) had a significantly worse overall survival (OS) and double the risk of death (hazard ratio (HR): 2.14; 95% confidence limits (CL) = 1.24–3.68; p-value = 0.006). Conversely, an inverse relationship between CTC median baseline number (6 CTC/3 mL of blood) and OS was observed. In addition, we found that in patients reporting stable disease (SD), the baseline cfDNA and CTCs were able to discriminate patients at high risk of poor survival. cfDNA demonstrated a more reliable biomarker than CTCs in the overall population. In the subgroup of SD patients, both biomarkers identified patients at high risk of poor prognosis who might deserve additional/alternative therapeutic interventions. View Full-Text
Keywords: liquid biopsy; circulating free DNA; circulating tumor cells; non-small cell lung cancer (NSCLC); biomarkers; chemotherapy liquid biopsy; circulating free DNA; circulating tumor cells; non-small cell lung cancer (NSCLC); biomarkers; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Coco, S.; Alama, A.; Vanni, I.; Fontana, V.; Genova, C.; Dal Bello, M.G.; Truini, A.; Rijavec, E.; Biello, F.; Sini, C.; Burrafato, G.; Maggioni, C.; Barletta, G.; Grossi, F. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Int. J. Mol. Sci. 2017, 18, 1035. https://doi.org/10.3390/ijms18051035

AMA Style

Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, Grossi F. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences. 2017; 18(5):1035. https://doi.org/10.3390/ijms18051035

Chicago/Turabian Style

Coco, Simona, Angela Alama, Irene Vanni, Vincenzo Fontana, Carlo Genova, Maria G. Dal Bello, Anna Truini, Erika Rijavec, Federica Biello, Claudio Sini, Giovanni Burrafato, Claudia Maggioni, Giulia Barletta, and Francesco Grossi. 2017. "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy" International Journal of Molecular Sciences 18, no. 5: 1035. https://doi.org/10.3390/ijms18051035

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop